Correlation Between Molecular Templates and Karyopharm Therapeutics
Can any of the company-specific risk be diversified away by investing in both Molecular Templates and Karyopharm Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Templates and Karyopharm Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Molecular Templates and Karyopharm Therapeutics, you can compare the effects of market volatilities on Molecular Templates and Karyopharm Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Templates with a short position of Karyopharm Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Templates and Karyopharm Therapeutics.
Diversification Opportunities for Molecular Templates and Karyopharm Therapeutics
-0.55 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Molecular and Karyopharm is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Templates and Karyopharm Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Karyopharm Therapeutics and Molecular Templates is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Templates are associated (or correlated) with Karyopharm Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Karyopharm Therapeutics has no effect on the direction of Molecular Templates i.e., Molecular Templates and Karyopharm Therapeutics go up and down completely randomly.
Pair Corralation between Molecular Templates and Karyopharm Therapeutics
Given the investment horizon of 90 days Molecular Templates is expected to generate 3.67 times more return on investment than Karyopharm Therapeutics. However, Molecular Templates is 3.67 times more volatile than Karyopharm Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Karyopharm Therapeutics is currently generating about 0.01 per unit of risk. If you would invest 50.00 in Molecular Templates on August 29, 2024 and sell it today you would lose (13.00) from holding Molecular Templates or give up 26.0% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Molecular Templates vs. Karyopharm Therapeutics
Performance |
| Timeline |
| Molecular Templates |
| Karyopharm Therapeutics |
Molecular Templates and Karyopharm Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Molecular Templates and Karyopharm Therapeutics
The main advantage of trading using opposite Molecular Templates and Karyopharm Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Templates position performs unexpectedly, Karyopharm Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Karyopharm Therapeutics will offset losses from the drop in Karyopharm Therapeutics' long position.| Molecular Templates vs. Bright Minds Biosciences | Molecular Templates vs. HP Inc | Molecular Templates vs. Intel | Molecular Templates vs. Chevron Corp |
| Karyopharm Therapeutics vs. X4 Pharmaceuticals | Karyopharm Therapeutics vs. Hookipa Pharma | Karyopharm Therapeutics vs. Mereo BioPharma Group | Karyopharm Therapeutics vs. Acumen Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Complementary Tools
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |